Relevance of serum biomarkers in the therapy of ventricular arrhythmias in cardiac sarcoidosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027545

Enrollment

Registered

2022-01-06

Start date

2021-09-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D86

Interventions

Group 1: determination of sIL2-R and ACE in patients with active inflammatory stage of cardiac sarcoidosis at the time of cardiac MRI Group 2: determination of sIL2-R and ACE in patients with chronic

Eligibility

Sex/Gender

All

Age

18 Years to 82 Years

Inclusion criteria

Inclusion criteria: biopsy-proven cardiac sarcoidosis with ventricular arrhythmias

Exclusion criteria

Exclusion criteria: age < 18 years

Design outcomes

Primary

Measure	Time frame
Determination of the relevance of the serum biomarkers sIL2-R and ACE in the treatment of ventricular arrhythmias in cardiac sarcoidosis	—

Secondary

Measure	Time frame
Clinical follow-up of patients with ventricular arrhythmias in cardiac sarcoidosis	—

Countries

Germany

Contacts

Public ContactChristopher Reithmann

HELIOS Klinikum München WestKardiologie und Internistische Intensivmedizin

christopher.reithmann@helios-gesundheit.de49 89 8892 2307

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026